GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Long-Term Debt

BCAL Diagnostics (ASX:BDX) Long-Term Debt : A$1.14 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Long-Term Debt?

BCAL Diagnostics's Long-Term Debt for the quarter that ended in Dec. 2023 was A$1.14 Mil.

BCAL Diagnostics's quarterly Long-Term Debt stayed the same from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$1.14 Mil).

BCAL Diagnostics Long-Term Debt Historical Data

The historical data trend for BCAL Diagnostics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Long-Term Debt Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Long-Term Debt
- -

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Debt Get a 7-Day Free Trial - - - - 1.14

BCAL Diagnostics  (ASX:BDX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BCAL Diagnostics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Long-Term Debt
Comparable Companies
ASX:GTG ASX:CTE ASX:LDX ASX:IBX ASX:RHY ASX:IIQ ASX:GSS ASX:MAP TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX
Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
Website
https://www.bcaldiagnostics.com
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.